RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Atul Humar, MD, MSc, FRCPC, FAST

Professor, Department of Medicine
University of Toronto
R. Fraser Elliott Chair, Transplantation
University Health Network
Director, University of Toronto Transplant Institute
Toronto, Ontario, Canada

Disclosures

Atul Humar, MD, MSc, FRCPC, FAST, has the following relevant financial relationships:
Consultant or advisor for: Astellas Pharma, Inc.; Roche; Takeda
Research funding from: Qiagen

Raymund R. Razonable, MD, FIDSA, FAST

Professor, Medicine
Program Director, Infectious Diseases Fellowship Program
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, Minnesota, United States

Disclosures

Raymund R. Razonable, MD, FIDSA, FAST, has the following relevant financial relationships:
Research funding from: Gilead Sciences, Inc.; Regeneron; Roche
Other (Data Adjudication Committee): AlloVir
Other (Data Safety Monitoring Board): Novartis

Fernanda P. Silveira, MD, MS, FIDSA, FAST

Director, Clinical Operations
Transplant Infectious Diseases
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States

Disclosures

Disclosure: Fernanda P. Silveira, MD, MS, FIDSA, FAST, has the following relevant financial relationships:
Consultant or advisor for: Eurofins Viracor; Janssen Pharmaceuticals; Takeda
Research funding from: Ansun Biopharma; Merck; Regeneron; Takeda

Patient
Patient participating in this activity has no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies.

CME / CE

Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum^®

Authors: Atul Humar, MD, MSc, FRCPC, FAST; Raymund R. Razonable, MD, FIDSA, FAST; Fernanda P. Silveira, MD, MS, FIDSA, FAST
CME / CE Released: 4/13/2023
Valid for credit through: 4/12/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

Transplantation, infectious diseases, nephrology, internal medicine, and pharmacy clinicians who manage patients with refractory or resistant cytomegalovirus (CMV) after solid organ transplantation.

The goal of this activity is to provide clinicians with the clinical tools necessary to identify and manage treatment-refractory and drug-resistant cytomegalovirus (CMV) in patients after solid organ transplantation (SOT). A panel of infectious diseases experts review current CMV treatment guidelines, discuss antiviral resistance testing, and provide insights for management with a new antiviral therapeutic option. An experienced patient with CMV provides important practical take-aways for clinicians to use with their own patients with SOT.

Upon completion of this activity, participants should be better be able to:

Employ current CMV treatment guidelines for the use of antiviral therapies and management of their adverse effects
Identify treatment-refractory and drug-resistant CMV by correctly interpreting antiviral resistance testing results
Select transplant patients who will benefit from the efficacy and reduced toxicity of new CMV therapy

Disclosures

Faculty

Atul Humar, MD, MSc, FRCPC, FAST

Professor, Department of Medicine
University of Toronto
R. Fraser Elliott Chair, Transplantation
University Health Network
Director, University of Toronto Transplant Institute
Toronto, Ontario, Canada

Disclosures

Atul Humar, MD, MSc, FRCPC, FAST, has the following relevant financial relationships:
Consultant or advisor for: Astellas Pharma, Inc.; Roche; Takeda
Research funding from: Qiagen

Raymund R. Razonable, MD, FIDSA, FAST

Professor, Medicine
Program Director, Infectious Diseases Fellowship Program
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, Minnesota, United States

Disclosures

Raymund R. Razonable, MD, FIDSA, FAST, has the following relevant financial relationships:
Research funding from: Gilead Sciences, Inc.; Regeneron; Roche
Other (Data Adjudication Committee): AlloVir
Other (Data Safety Monitoring Board): Novartis

Fernanda P. Silveira, MD, MS, FIDSA, FAST

Director, Clinical Operations
Transplant Infectious Diseases
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States

Disclosures

Disclosure: Fernanda P. Silveira, MD, MS, FIDSA, FAST, has the following relevant financial relationships:
Consultant or advisor for: Eurofins Viracor; Janssen Pharmaceuticals; Takeda
Research funding from: Ansun Biopharma; Merck; Regeneron; Takeda

Patient
Patient participating in this activity has no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies.

Accreditation Statements

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For Pharmacists

RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008290-0000-23-005-H01-P)
Type of Activity: Knowledge

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum^®

Authors: Atul Humar, MD, MSc, FRCPC, FAST; Raymund R. Razonable, MD, FIDSA, FAST; Fernanda P. Silveira, MD, MS, FIDSA, FASTFaculty and Disclosures

CME / CE Released: 4/13/2023

Valid for credit through: 4/12/2024, 11:59 PM EST

processing....

Audience Q&A

« Return to: Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum^®

CME / CE Information Download Slides

Print
Like Tweet

Faculty and Disclosures

Faculty

Atul Humar, MD, MSc, FRCPC, FAST

Raymund R. Razonable, MD, FIDSA, FAST

Fernanda P. Silveira, MD, MS, FIDSA, FAST

CME / CE

Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum®

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Atul Humar, MD, MSc, FRCPC, FAST

Raymund R. Razonable, MD, FIDSA, FAST

Fernanda P. Silveira, MD, MS, FIDSA, FAST

Accreditation Statements

For Physicians

For Pharmacists

Instructions for Participation and Credit

Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum®

Audience Q&A

Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum^®

Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum^®